Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIANO: NI-0801 in PBC with incomplete response to UDCA
NCT01430429Phase 2Terminated
- Sponsor
- Lightchain Bioscience
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of NI-0801 in primary biliary cholangitis (PBC), sponsored by Lightchain Bioscience. Primary endpoint: Percentage change from baseline in serum alkaline phosphatase at 12 weeks. Status: terminated.
02
Drugs
NI-0801
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT01430429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01430429.